This trial is testing a new drug to see if it's safe and effective in cancer patients with a specific genetic mutation. Patients who have already tried the standard of care and couldn't tolerate it are eligible. The trial will last up to 2 years.
2 Primary · 9 Secondary · Reporting Duration: Estimated up to 2 years
360 Total Participants · 2 Treatment Groups
Primary Treatment: LY3537982 · No Placebo Group · Phase 1
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|Hoag Memorial Hospital Presbyterian||100.0%|